ClinicalTrials.gg
RecruitingNCT07061977Updated Nov 9, 2026

Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

A Phase 3 interventional study of Biospecimen Collection and Brachytherapy in Locally Advanced Cervical Adenocarcinoma, Locally Advanced Cervical Adenosquamous Carcinoma and Locally Advanced Cervical Squamous Cell Carcinoma, sponsored by National Cancer Institute (NCI). Recruiting at 347 sites in 2 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by National Cancer Institute (NCI) · Phase 3, Interventional, and Treatment

How we know · 9 judgments

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.
Updated Nov 9, 2026Site recruiting status changed15 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
336
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in Carcinoma, Adenosquamous with a site in United States — 4 open to participants now, 7 under way, 1 of them phase 3. Carcinoma, Adenosquamous · United States.

Planned enrollment
4th of 23
336 · median 37
Started
2025
with 1 other
Phase 3
4 of 23
1 open now
Registered
23rd of 23
by date
Lead sponsor
9 of 23
National Cancer Institute (NCI)

Among the 23 studies in Carcinoma, Adenosquamous with a site in United States, this one is the 4th largest by planned enrollment, is one of 2 that started in 2025, is one of 4 in phase 3, and was the 23rd registered.

Carcinoma, Adenosquamous

33 studies on the registry are indexed under Carcinoma, Adenosquamous; 7 are open to participants now.

Browse Carcinoma, Adenosquamous studies →

Open to participants now

4 of the 23 studies in Carcinoma, Adenosquamous with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 6 Carcinoma, Adenosquamous studies recruiting now, 4 set no upper age limit and 2 stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Carcinoma, Adenosquamous with a site in United States, or all of them as a file.
02

Study summary

This phase III trial compares the addition of induction chemotherapy, with carboplatin, paclitaxel and pembrolizumab, to chemotherapy and radiation, with cisplatin and pembrolizumab followed by pembrolizumab maintenance for the treatment of patients with cervical cancer that has spread to nearby tissue or lymph nodes (locally advanced). Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Paclitaxel is in a class of medications called antimicrotubule agents. It stops cancer cells from growing and dividing and may kill them. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of cancer cells. Adding induction chemotherapy to the usual treatment of chemotherapy and radiation followed by maintenance may be more effective in treating patients with high risk, locally advanced cervical cancer.

Read the detailed description

PRIMARY OBJECTIVE:

I. To determine whether induction immunotherapy (IO) and chemotherapy prior to concurrent chemoradiation therapy (CCRT) + IO improves progression-free survival (PFS) compared to CCRT+IO alone.

SECONDARY OBJECTIVES:

I. To assess whether induction IO and chemotherapy prior to CCRT+IO improves the overall survival (OS) compared to CCRT+IO alone.

II. To determine the nature and degree of toxicity of induction IO and chemotherapy prior to CCRT + IO as compared to concurrent CCRT+IO as assessed by Common Terminology Criteria for Adverse Events (CTCAE) version (v) 5.0.

III. To determine the impact on CCRT start, CCRT completion time, and number of cycles of cisplatin administered; with induction IO and chemotherapy prior to CCRT+IO arm as compared to CCRT+IO.

IV. To assess the association between allostatic load and PFS/OS. V. To assess the predictive value of the integrated biomarker: PD-L1 expression at baseline for progression free survival.

VI. To assess the prognostic and predictive value of the integrated biomarker: circulating tumor deoxyribonucleic acid (ctDNA) at baseline and at 3 months post radiation therapy (RT) for progression free survival.

VII. To explore radiotherapy quality pretreatment scores conducted by expert review with assistance from artificial intelligence (AI) models and correlation with outcomes.

EXPLORATORY OBJECTIVES:

I. To assess the evolution of T cell receptor (TCR) repertoire on treatment and its correlation with clinical outcomes.

II. To identify pre-treatment tumor microenvironment biomarkers predictive of outcomes.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM 1:

CHEMORADIATION: Patients receive cisplatin intravenously (IV) once weekly (QW) for 5 weeks and pembrolizumab IV over 30 minutes every 3 weeks (Q3W) for 5 doses. Patients also undergo radiation therapy once daily 5 days per week for 25-29 treatments in weeks 1-5 followed by brachytherapy up to twice per week for 4-5 treatments in weeks 5-7. Treatment is given in the absence of disease progression or unacceptable toxicity

MAINTENANCE: Patients receive pembrolizumab IV over 30 minutes every 6 weeks (Q6W) for 15 cycles in the absence of disease progression or unacceptable toxicity.

Patients undergo positron emission tomography (PET) scan, computed tomography (CT) scan, chest x-ray and/or magnetic resonance imaging (MRI) and blood sample collection throughout the study.

ARM 2:

INDUCTION: Patients receive carboplatin IV and paclitaxel IV QW on weeks 1-3 and pembrolizumab IV over 30 minutes Q3W on weeks 1 for each cycle. Cycles repeat every 3 weeks for 2 cycles in the absence of disease progression or unacceptable toxicity.

CHEMORADIATION: Patients receive cisplatin IV QW for 5 weeks and pembrolizumab IV over 30 minutes every Q3W for 5 doses. Patients also undergo radiation therapy once daily 5 days per week for 25-29 treatments in weeks 7-11 followed by brachytherapy up to twice per week for 4-5 treatments in weeks 11-13. Treatment is given in the absence of disease progression or unacceptable toxicity

MAINTENANCE: Patients receive pembrolizumab IV over 30 minutes Q6W for 14 cycles in the absence of disease progression or unacceptable toxicity.

Patients undergo PET scan, CT scan, chest x-ray and/or MRI and blood sample collection throughout the study.

After completion of study treatment, patients are followed up every 3 months for 2 years then every 6 months for 3 years.

03

Conditions studied

  • Locally Advanced Cervical Adenocarcinoma
  • Locally Advanced Cervical Adenosquamous Carcinoma
  • Locally Advanced Cervical Squamous Cell Carcinoma
  • Stage IIIA Cervical Cancer FIGO 2018
  • Stage IIIB Cervical Cancer FIGO 2018
  • Stage IIIC1 Cervical Cancer FIGO 2018
  • Stage IIIC2 Cervical Cancer FIGO 2018
  • Stage IVA Cervical Cancer FIGO 2018
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Patients must have confirmed newly diagnosed cervical cancer. Eligible pathologic types: squamous cell carcinoma, adenocarcinoma, adenosquamous cell carcinoma
  • Patients must have locally advanced cervical cancer (LACC) with T3 or T4 disease with or without lymph node involvement:

    • IIIA (T3aN0M0)
    • IIIB (T3bN0M0)
    • IIIC1(T3aN1M0, T3bN1M0)
    • IIIC2 (T3aN2M0, T3bN2M0)
    • IVA (T4aN0M0, T4aN1M0, T4aN2M0) No prior hysterectomy defined as removal of the entire uterus.
    • NOTE: prior partial/subtotal hysterectomy for reasons other than cervical cancer are eligible to participate in the study. No plan to perform a hysterectomy as part of initial cervical cancer therapy.

No paraaortic lymph node (PALN) above the T12/L1 interspace.

  • Note: Nodal status can be confirmed by imaging (CT, MRI, or PET/CT), fine needle aspirate/core , extra peritoneal biopsy, laparoscopic biopsy, or lymphadenectomy.

Radiologic definition of lymph node staging:

  • N1:

    • One or more pelvic lymph nodes with short axis diameter of ≥ 15 mm (axial plane) by CT or MRI, and/or
    • One or more pelvic lymph nodes with short axis diameter of ≥ 10 mm and standardized uptake value maximum (SUVmax) ≥ 2.5 by fludeoxyglucose (FDG)-PET
  • N2:

    • One or more para-aortic lymph node with short axis diameter of ≥ 15 mm (axial plane) by CT or MRI, and/or
    • One or more para-aortic lymph node with short axis diameter of ≥ 10 mm and SUVmax ≥ 2.5 by FDG-PET

      • No prior definitive surgical, radiation, or systemic therapy for cervical cancer
      • No prior immunotherapy
      • No prior pelvic radiation therapy for any disease
      • Age ≥ 18
      • (ECOG) performance status of ≤ 2
      • Not pregnant and not nursing
      • (ANC) ≥ 1,500 cells/mm\^3
      • ≥ 100,000 cells/mm\^3
      • ≥ 8 g/dl (Note: The use of transfusion or other intervention to achieve hemoglobulin [Hgb] ≥ 8 g/dl is acceptable)
      • (CrCL) of ≥ 50 mL/min by the Cockcroft-Gault formula
      • Total ≤ 1.5 x institutional (ULN) (patients with known Gilbert's disease who have bilirubin level ≤ 3 x institutional ULN may be enrolled)
      • (AST) and alanine aminotransferase (ALT) ≤ 3 x institutional ULN
      • Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the Functional Classification. To be eligible for this trial, patients should be class 2B or better
      • No active infection requiring parenteral antibiotics
      • No within 30 days prior to registration. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacille Calmette Guerin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines are live attenuated vaccines and are not allowed
      • No diagnosis of immunodeficiency or is receiving chronic systemic therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of therapy within 7 days prior registration
      • No active disease that has required systemic treatment in past 2 years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed
      • No history of (non-infectious) pneumonitis that required steroids, or current pneumonitis
      • No history of allergic reaction to the study agent(s) or compounds of similar chemical or biologic composition to the study agent(s) (or any of its )
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
336 participants (estimated)

Study arms

  • Active comparator
    Arm 1 (Standard care)

    CHEMORADIATION: Patients receive cisplatin IV QW for 5 weeks and pembrolizumab IV over 30 minutes Q3W for 5 doses. Patients also undergo radiation therapy with EBRT or IMRT once daily 5 days per week for 25-29 treatments in weeks 1-5 followed by brachytherapy up to twice per week for 4-5 treatments in weeks 5-7. Treatment is given in the absence of disease progression or unacceptable toxicity MAINTENANCE: Patients receive pembrolizumab IV over 30 minutes Q6W for 14 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo PET scan, CT scan, chest x-ray and/or MRI and blood sample collection throughout the study.

    Procedure: Biospecimen Collection · Radiation: Brachytherapy · Procedure: Chest Radiography · Drug: Cisplatin · Procedure: Computed Tomography · Radiation: External Beam Radiation Therapy · Radiation: Intensity-Modulated Radiation Therapy · Procedure: Magnetic Resonance Imaging · Biological: Pembrolizumab · Procedure: Positron Emission Tomography

  • Experimental
    Arm 2 (induction and standard care)

    INDUCTION: Patients receive carboplatin IV and paclitaxel IV QW on weeks 1-3 and pembrolizumab IV over 30 minutes Q3W on week 1 for each cycle. Cycles repeat every 3 weeks for 2 cycles in the absence of disease progression or unacceptable toxicity. CHEMORADIATION: Patients receive cisplatin IV QW for 5 weeks and pembrolizumab IV over 30 minutes every Q3W for 5 doses. Patients also undergo radiation therapy with EBRT or IMRT once daily 5 days per week for 25-29 treatments in weeks 7-11 followed by brachytherapy up to twice per week for 4-5 treatments in weeks 11-13. Treatment is given in the absence of disease progression or unacceptable toxicity MAINTENANCE: Patients receive pembrolizumab IV over 30 minutes Q6W for 14 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo PET scan, CT scan, chest x-ray and/or MRI and blood sample collection throughout the study.

    Procedure: Biospecimen Collection · Radiation: Brachytherapy · Drug: Carboplatin · Procedure: Chest Radiography · Drug: Cisplatin · Procedure: Computed Tomography · Radiation: External Beam Radiation Therapy · Radiation: Intensity-Modulated Radiation Therapy · Procedure: Magnetic Resonance Imaging · Drug: Paclitaxel · Biological: Pembrolizumab · Procedure: Positron Emission Tomography

Interventions

  • ProcedureBiospecimen Collection

    Undergo blood sample collection

    Also known as: Biological Sample Collection, Biospecimen Collected, Sample Collection, Specimen Collection

  • RadiationBrachytherapy

    Undergo brachytherapy

    Also known as: Brachytherapy, NOS, Internal Radiation, Internal Radiation Brachytherapy, Internal Radiation Therapy, Radiation Brachytherapy, Radiation, Internal

  • Given IV

    Also known as: Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo

  • ProcedureChest Radiography

    Undergo chest x-ray

    Also known as: Chest X-ray

  • Given IV

    Also known as: Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin

  • ProcedureComputed Tomography

    Undergo CT scan

    Also known as: CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, Diagnostic CAT Scan, Diagnostic CAT Scan Service Type, tomography

  • RadiationExternal Beam Radiation Therapy

    Undergo EBRT

    Also known as: Definitive Radiation Therapy, EBRT, External Beam Radiation, External Beam Radiotherapy, External Beam Radiotherapy (conventional), External Beam RT, external radiation, External Radiation Therapy, external-beam radiation, Radiation, External Beam, Teleradiotherapy, Teletherapy, Teletherapy Radiation

  • RadiationIntensity-Modulated Radiation Therapy

    Undergo IMRT

    Also known as: IMRT, Intensity modulated radiation therapy (procedure), Intensity Modulated RT, Intensity-Modulated Radiotherapy, Radiation, Intensity-Modulated Radiotherapy

  • ProcedureMagnetic Resonance Imaging

    Undergo MRI

    Also known as: Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI

  • Given IV

    Also known as: Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat

  • BiologicalPembrolizumab

    Given IV

    Also known as: BCD-201, GME 751, GME751, Keytruda, Lambrolizumab, MK 3475, MK-3475, MK3475, Pembrolizumab Biosimilar BCD-201, Pembrolizumab Biosimilar GME751, Pembrolizumab Biosimilar QL2107, Pembrolizumab Biosimilar RPH-075, Pembrolizumab Biosimilar SB27, QL2107, RPH 075, RPH-075, RPH075, SB 27, SB-27, SB27, SCH 900475, SCH-900475, SCH900475

  • ProcedurePositron Emission Tomography

    Undergo PET scan

    Also known as: Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, PT

06

What researchers measure

Primary outcomes

  1. Progression free survival (PFS)

    Analysis will be performed using a one-sided log-rank test stratified by factors declared at randomization when (at least) 190 PFS events are observed in both arms. Patients will be grouped by their randomized treatment for intention-to-treat (ITT) analyses, supported by patients in ITT population. Treatment hazard ratio and confidence will be estimated using Cox proportional hazard models specified with a main effect for the randomized treatment assignment and stratified by factors declared at randomization. PFS at 2 years will be estimated using Kaplan-Meier method for each arm.

    Time frame: From randomization to time of progression or death from any cause, whichever occurs first, or date of last contact if neither progression nor death has occurred, up to 7 years

Secondary outcomes

  1. Overall survival (OS)

    The OS treatment hypothesis test (Arm 2 versus \[vs.\] Arm 1) will be based on a 1-sided log-rank test, stratified by the factors specified at randomization. Comparisons of the OS distributions by treatment arm will be described using Kaplan-Meier methods. Treatment hazard ratio estimates and their 95% confidence intervals will be estimated using a multivariable proportional hazards model specified with main effects for the randomized treatment assignment (Arm 2 vs Arm 1) and stratified by the factors declared at randomization.

    Time frame: From randomization to death from any cause, up to 7 years

  2. Incidence of adverse events (AEs)

    Assessed by Common Terminology Criteria for Adverse Events version 5.0. The nature, frequency, and degree of toxicity will be tabulated at the System Organ Class and AE-specific term levels. Tabulations will show the number and percentage of patients by maximum grade, within the treatment group received, regardless of the randomized treatment assignment. Differences in the level of toxicities by treatment arm will be assessed by classifying them as severe (grade 3 or higher) or not severe (grade 2 or lower) and examining the relative proportion of severe toxicities by Fisher's exact test.

    Time frame: Up to 7 years

  3. Duration of concurrent chemoradiation therapy (CCRT) completion

    Will be summarized and compared using 2-sample Wilcoxon rank sum tests. The proportion of patients with a delayed time to initiate CCRT by 2 weeks or more will be estimated and investigated by Fisher's exact test.

    Time frame: From CCRT start date to CCRT end date

  4. Number of cycles of cisplatin

    Will be summarized and compared using 2-sample Wilcoxon rank sum tests.

    Time frame: From 7 days after the last dose of induction chemotherapy to the CCRT start date for Arm 2, the planned CCRT start date to actual CCRT start date for Arm 1

  5. Allostatic load

    Will be summarized by treatment arm, and its association with OS will be evaluated using Cox PH model adjusted with main effects for the randomized treatment assignment (Arm 2 vs Arm 1) and stratified by the factors declared at randomization.

    Time frame: Up to 2 years

  6. Tumor PD-L1 expression

    The predictive value of tumor PD-L1 expression at baseline for PFS will be investigated using Cox PH model adjusted with main effects for the randomized treatment assignment (Arm 2 vs Arm 1) and stratified by the factors declared at randomization.

    Time frame: At baseline

  7. Circulating tumor deoxyribonucleic acid expression

    Will be summarized by treatment arm and by collection time. Will be investigated using Cox PH model adjusted with main effects for the randomized treatment assignment (Arm 2 vs Arm 1) and stratified by the factors declared at randomization.

    Time frame: At baseline and at 3 months post radiation therapy

  8. Radiation quality pre-treatment score

    Will be summarized by treatment arm, and its associations with PFS and OS will be evaluated using Cox PH model adjusted with main effects for the randomized treatment assignment (Arm 2 vs Arm 1) and stratified by the factors declared at randomization.

    Time frame: At time of radiation

Other outcomes

  1. T cell receptor (TCR) expression

    Will be summarized by treatment arm, and its correlation with PFS/OS will be investigated using Cox PH model adjusted with main effects for the randomized treatment assignment (Arm 2 vs Arm 1) and stratified by the factors declared at randomization. Repeated measure methods (e.g., linear mixed model) will be used for exploration of TCR evolution/trajectory on treatment.

    Time frame: Up to 7 years

  2. Tumor microenvironment

    The predictive values of each of the pre-treatment tumor microenvironment biomarkers for PFS and OS will be investigated using Cox PH model adjusted with main effects for the randomized treatment assignment (Arm 2 vs Arm 1) and stratified by the factors declared at randomization.

    Time frame: At baseline

07

Study locations

340 of 347 sites recruiting

Showing the first 100 of 347 sites across 2 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.

Data sharing details ↗ · grants.nih.gov

No publications or documents are linked to this record.

09

Timeline

22 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2025 (actual). Primary completion is estimated for Dec 2030, 61 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 11, 2025
First posted
Jul 14, 2025
StartActual
Nov 5, 2025
Primary completionEst.
Dec 31, 2030
CompletionEst.
Dec 31, 2030
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
15 sites added, 1 site removed. 5 sites changed recruiting status (4 now recruiting, 1 now suspended)
Show 5 sites
  • Upper Valley Medical Center · Troy, United StatesSuspended→Recruiting
  • Clackamas Radiation Oncology Center · Clackamas, United StatesSuspended→Recruiting
  • Providence Newberg Medical Center · Newberg, United StatesSuspended→Recruiting
  • Providence Willamette Falls Medical Center · Oregon City, United StatesSuspended→Recruiting
  • Nebraska Methodist Hospital · Omaha, United StatesRecruiting→Suspended
Show 15 added (14 United States, 1 Puerto Rico)
  • United Hospital Center · Bridgeport, United States
  • Miami Cancer Institute · Miami, United States
  • Doctors Cancer Center · Manati, Puerto Rico
  • Vandalia Health/CAMC Institute for Academic Medicine · Charleston, United States
  • Memorial Hospital of Laramie County · Cheyenne, United States
  • Cedars-Sinai Medical Center · Los Angeles, United States
  • Beth Israel Deaconess Medical Center · Boston, United States
  • Corewell Health Beaumont Troy Hospital · Troy, United States
  • University of Vermont Medical Center · Burlington, United States
  • University of Vermont and State Agricultural College · Burlington, United States
  • Hayworth Cancer Center · High Point, United States
  • Sutter Medical Center Sacramento · Sacramento, United States
  • John H Stroger Jr Hospital of Cook County · Chicago, United States
  • California Pacific Medical Center-Pacific Campus · San Francisco, United States
  • Augusta University Medical Center · Augusta, United States
Show 1 removed
  • West Virginia University Charleston Division · Charleston, United States
across 21 updates, Sep 25, 2026 – Nov 9, 2026
Site contacts
Changed at 26 sites. See the sites
Show 26 sites
  • Florida Cancer Specialists - Sarasota Downtown · Sarasota, United StatesContact added C•••@flcancer.com · •••9930Contact added (no phone or email listed)
  • Florida Cancer Specialists - Venice Pinebrook · Venice, United StatesContact added C•••@flcancer.com · •••9930Contact added (no phone or email listed)
  • West Virginia University Charleston Division · Charleston, United StatesContact none listed→C•••@vandaliahealth.org
  • Regions Hospital · Saint Paul, United StatesContact person changed (no phone or email listed)
  • Cancer Center of Western Wisconsin · New Richmond, United StatesContact person changed (no phone or email listed)
  • Midwestern Regional Medical Center · Zion, United StatesContact added •••0745Contact added (no phone or email listed)
  • Aultman Health Foundation · Canton, United StatesContact added C•••@aultman.com · •••7274Contact added (no phone or email listed)
  • Providence Portland Medical Center · Portland, United StatesContact added C•••@providence.org · •••2614Contact added (no phone or email listed)
  • Providence Saint Vincent Medical Center · Portland, United StatesContact added C•••@providence.org · •••2614Contact added (no phone or email listed)
  • Upper Valley Medical Center · Troy, United StatesContact added c•••@daytonncorp.org · •••2900Contact added (no phone or email listed)
  • Clackamas Radiation Oncology Center · Clackamas, United StatesContact added C•••@providence.org · •••2614Contact added (no phone or email listed)
  • Providence Newberg Medical Center · Newberg, United StatesContact added C•••@providence.org · •••2614Contact added (no phone or email listed)
  • Providence Willamette Falls Medical Center · Oregon City, United StatesContact added C•••@providence.org · •••2614Contact added (no phone or email listed)
  • Saint Luke's Cancer Center - Allentown · Allentown, United StatesContact added •••4714Contact added (no phone or email listed)
  • Saint Luke's University Hospital-Bethlehem Campus · Bethlehem, United StatesContact added •••4151Contact added (no phone or email listed)
  • Saint Luke's Hospital-Anderson Campus · Easton, United StatesContact added R•••@nrgoncology.org · •••5294Contact added (no phone or email listed)
  • Saint Luke's Hospital - Upper Bucks Campus · Quakertown, United StatesContact added •••4714Contact added (no phone or email listed)
  • Saint Luke's Hospital - Monroe Campus · Stroudsburg, United StatesContact added R•••@nrgoncology.org · •••5294Contact added (no phone or email listed)
  • ProMedica Flower Hospital · Sylvania, United StatesContact added P•••@promedica.org · •••1842Contact added (no phone or email listed)
  • Jersey City Medical Center · Jersey City, United StatesContact added R•••@nrgoncology.org · •••5294Contact added (no phone or email listed)
  • Cooperman Barnabas Medical Center · Livingston, United StatesContact added •••5200Contact added (no phone or email listed)
  • Monmouth Medical Center · Long Branch, United StatesContact added m•••@rwjbh.org · •••6564Contact added (no phone or email listed)
  • Rutgers Cancer Institute of New Jersey · New Brunswick, United StatesContact added •••7356Contact added (no phone or email listed)
  • Rutgers New Jersey Medical School · Newark, United StatesContact added •••7356Contact added (no phone or email listed)
  • Community Medical Center · Toms River, United StatesContact added L•••@rwjbh.org · •••8294Contact added (no phone or email listed)
  • Nebraska Methodist Hospital · Omaha, United StatesContact removed •••5144Contact removed (no phone or email listed)
across 15 updates, Sep 28, 2026 – Nov 6, 2026
Show all 22 updates
  1. Nov 9, 2026
    1 site added
    Show site
    • Augusta University Medical Center · Augusta, United States
  2. Nov 6, 2026
    6 sites changed recruiting status (6 now recruiting)
    Show 6 sites
    • Midwestern Regional Medical Center · Zion, United StatesSuspended→Recruiting
    • Saint Luke's Cancer Center - Allentown · Allentown, United StatesSuspended→Recruiting
    • Saint Luke's University Hospital-Bethlehem Campus · Bethlehem, United StatesSuspended→Recruiting
    • Saint Luke's Hospital-Anderson Campus · Easton, United StatesSuspended→Recruiting
    • Saint Luke's Hospital - Upper Bucks Campus · Quakertown, United StatesSuspended→Recruiting
    • Saint Luke's Hospital - Monroe Campus · Stroudsburg, United StatesSuspended→Recruiting
    Site contacts Changed at 6 sites. See the sites
    Show 6 sites
    • Midwestern Regional Medical Center · Zion, United StatesContact added •••0745Contact added (no phone or email listed)
    • Saint Luke's Cancer Center - Allentown · Allentown, United StatesContact added •••4714Contact added (no phone or email listed)
    • Saint Luke's University Hospital-Bethlehem Campus · Bethlehem, United StatesContact added •••4151Contact added (no phone or email listed)
    • Saint Luke's Hospital-Anderson Campus · Easton, United StatesContact added R•••@nrgoncology.org · •••5294Contact added (no phone or email listed)
    • Saint Luke's Hospital - Upper Bucks Campus · Quakertown, United StatesContact added •••4714Contact added (no phone or email listed)
    • Saint Luke's Hospital - Monroe Campus · Stroudsburg, United StatesContact added R•••@nrgoncology.org · •••5294Contact added (no phone or email listed)
  3. Nov 5, 2026
    6 sites changed recruiting status (5 now suspended, 1 now recruiting)
    Show 6 sites
    • Rutgers Cancer Institute of New Jersey · New Brunswick, United StatesSuspended→Recruiting
    • Saint Luke's Cancer Center - Allentown · Allentown, United StatesRecruiting→Suspended
    • Saint Luke's University Hospital-Bethlehem Campus · Bethlehem, United StatesRecruiting→Suspended
    • Saint Luke's Hospital-Anderson Campus · Easton, United StatesRecruiting→Suspended
    • Saint Luke's Hospital - Upper Bucks Campus · Quakertown, United StatesRecruiting→Suspended
    • Saint Luke's Hospital - Monroe Campus · Stroudsburg, United StatesRecruiting→Suspended
    Site contacts Changed at 6 sites. See the sites
    Show 6 sites
    • Rutgers Cancer Institute of New Jersey · New Brunswick, United StatesContact added •••7356Contact added (no phone or email listed)
    • Saint Luke's Cancer Center - Allentown · Allentown, United StatesContact removed •••4714Contact removed (no phone or email listed)
    • Saint Luke's University Hospital-Bethlehem Campus · Bethlehem, United StatesContact removed •••4151Contact removed (no phone or email listed)
    • Saint Luke's Hospital-Anderson Campus · Easton, United StatesContact removed R•••@nrgoncology.org · •••5294Contact removed (no phone or email listed)
    • Saint Luke's Hospital - Upper Bucks Campus · Quakertown, United StatesContact removed •••4714Contact removed (no phone or email listed)
    • Saint Luke's Hospital - Monroe Campus · Stroudsburg, United StatesContact removed R•••@nrgoncology.org · •••5294Contact removed (no phone or email listed)
  4. Nov 4, 2026
    Nebraska Methodist Hospital is now Suspended
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Nebraska Methodist Hospital · Omaha, United StatesContact removed •••5144Contact removed (no phone or email listed)
  5. Nov 2, 2026
    Rutgers Cancer Institute of New Jersey is now Suspended
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Rutgers Cancer Institute of New Jersey · New Brunswick, United StatesContact removed •••7356Contact removed (no phone or email listed)
  6. Oct 28, 2026
    1 site added
    Show site
    • California Pacific Medical Center-Pacific Campus · San Francisco, United States
  7. Oct 26, 2026
    1 site added. ProMedica Flower Hospital is now Recruiting
    Show site
    • John H Stroger Jr Hospital of Cook County · Chicago, United States
    Site contacts Changed at 1 site. See the sites
    Show the site
    • ProMedica Flower Hospital · Sylvania, United StatesContact added P•••@promedica.org · •••1842Contact added (no phone or email listed)
  8. Oct 22, 2026
    1 site added. 6 sites changed recruiting status (6 now recruiting)
    Show 6 sites
    • Jersey City Medical Center · Jersey City, United StatesSuspended→Recruiting
    • Cooperman Barnabas Medical Center · Livingston, United StatesSuspended→Recruiting
    • Monmouth Medical Center · Long Branch, United StatesSuspended→Recruiting
    • Rutgers Cancer Institute of New Jersey · New Brunswick, United StatesSuspended→Recruiting
    • Rutgers New Jersey Medical School · Newark, United StatesSuspended→Recruiting
    • Community Medical Center · Toms River, United StatesSuspended→Recruiting
    Show site
    • Sutter Medical Center Sacramento · Sacramento, United States
    Site contacts Changed at 6 sites. See the sites
    Show 6 sites
    • Jersey City Medical Center · Jersey City, United StatesContact added R•••@nrgoncology.org · •••5294Contact added (no phone or email listed)
    • Cooperman Barnabas Medical Center · Livingston, United StatesContact added •••5200Contact added (no phone or email listed)
    • Monmouth Medical Center · Long Branch, United StatesContact added m•••@rwjbh.org · •••6564Contact added (no phone or email listed)
    • Rutgers Cancer Institute of New Jersey · New Brunswick, United StatesContact added •••7356Contact added (no phone or email listed)
    • Rutgers New Jersey Medical School · Newark, United StatesContact added •••7356Contact added (no phone or email listed)
    • Community Medical Center · Toms River, United StatesContact added L•••@rwjbh.org · •••8294Contact added (no phone or email listed)
  9. Oct 21, 2026
    1 site added. 6 sites changed recruiting status (6 now suspended)
    Show 6 sites
    • Jersey City Medical Center · Jersey City, United StatesRecruiting→Suspended
    • Cooperman Barnabas Medical Center · Livingston, United StatesRecruiting→Suspended
    • Monmouth Medical Center · Long Branch, United StatesRecruiting→Suspended
    • Rutgers Cancer Institute of New Jersey · New Brunswick, United StatesRecruiting→Suspended
    • Rutgers New Jersey Medical School · Newark, United StatesRecruiting→Suspended
    • Community Medical Center · Toms River, United StatesRecruiting→Suspended
    Show site
    • Hayworth Cancer Center · High Point, United States
    Site contacts Changed at 6 sites. See the sites
    Show 6 sites
    • Jersey City Medical Center · Jersey City, United StatesContact removed R•••@nrgoncology.org · •••5294Contact removed (no phone or email listed)
    • Cooperman Barnabas Medical Center · Livingston, United StatesContact removed •••5200Contact removed (no phone or email listed)
    • Monmouth Medical Center · Long Branch, United StatesContact removed m•••@rwjbh.org · •••6564Contact removed (no phone or email listed)
    • Rutgers Cancer Institute of New Jersey · New Brunswick, United StatesContact removed •••7356Contact removed (no phone or email listed)
    • Rutgers New Jersey Medical School · Newark, United StatesContact removed •••7356Contact removed (no phone or email listed)
    • Community Medical Center · Toms River, United StatesContact removed L•••@rwjbh.org · •••8294Contact removed (no phone or email listed)
  10. Oct 19, 2026
    2 sites added. ProMedica Flower Hospital is now Suspended
    Show 2 added (2 United States)
    • University of Vermont Medical Center · Burlington, United States
    • University of Vermont and State Agricultural College · Burlington, United States
    Site contacts Changed at 1 site. See the sites
    Show the site
    • ProMedica Flower Hospital · Sylvania, United StatesContact removed P•••@promedica.org · •••1842Contact removed (no phone or email listed)
  11. Oct 16, 2026
    Site contacts Changed at 5 sites. See the sites
    Show 5 sites
    • Saint Luke's Cancer Center - Allentown · Allentown, United StatesContact person changed (no phone or email listed)
    • Saint Luke's University Hospital-Bethlehem Campus · Bethlehem, United StatesContact person changed (no phone or email listed)
    • Saint Luke's Hospital-Anderson Campus · Easton, United StatesContact person changed (no phone or email listed)
    • Saint Luke's Hospital - Upper Bucks Campus · Quakertown, United StatesContact person changed (no phone or email listed)
    • Saint Luke's Hospital - Monroe Campus · Stroudsburg, United StatesContact person changed (no phone or email listed)
  12. Oct 14, 2026
    5 sites changed recruiting status (5 now recruiting)
    Show 5 sites
    • Clackamas Radiation Oncology Center · Clackamas, United StatesSuspended→Recruiting
    • Providence Newberg Medical Center · Newberg, United StatesSuspended→Recruiting
    • Providence Willamette Falls Medical Center · Oregon City, United StatesSuspended→Recruiting
    • Providence Portland Medical Center · Portland, United StatesSuspended→Recruiting
    • Providence Saint Vincent Medical Center · Portland, United StatesSuspended→Recruiting
    Site contacts Changed at 5 sites. See the sites
    Show 5 sites
    • Clackamas Radiation Oncology Center · Clackamas, United StatesContact added C•••@providence.org · •••2614Contact added (no phone or email listed)
    • Providence Newberg Medical Center · Newberg, United StatesContact added C•••@providence.org · •••2614Contact added (no phone or email listed)
    • Providence Willamette Falls Medical Center · Oregon City, United StatesContact added C•••@providence.org · •••2614Contact added (no phone or email listed)
    • Providence Portland Medical Center · Portland, United StatesContact added C•••@providence.org · •••2614Contact added (no phone or email listed)
    • Providence Saint Vincent Medical Center · Portland, United StatesContact added C•••@providence.org · •••2614Contact added (no phone or email listed)
  13. Oct 13, 2026
    1 site added
    Show site
    • Corewell Health Beaumont Troy Hospital · Troy, United States
  14. Oct 9, 2026
    1 site added
    Show site
    • Beth Israel Deaconess Medical Center · Boston, United States
  15. Oct 8, 2026
    1 site added
    Show site
    • Cedars-Sinai Medical Center · Los Angeles, United States
  16. Oct 7, 2026
    2 sites changed recruiting status (2 now recruiting)
    Show 2 sites
    • Aultman Health Foundation · Canton, United StatesSuspended→Recruiting
    • Upper Valley Medical Center · Troy, United StatesSuspended→Recruiting
    Site contacts Changed at 2 sites. See the sites
    Show 2 sites
    • Aultman Health Foundation · Canton, United StatesContact added C•••@aultman.com · •••7274Contact added (no phone or email listed)
    • Upper Valley Medical Center · Troy, United StatesContact added c•••@daytonncorp.org · •••2900Contact added (no phone or email listed)
  17. Oct 6, 2026
    4 sites changed recruiting status (4 now suspended)
    Show 4 sites
    • Midwestern Regional Medical Center · Zion, United StatesRecruiting→Suspended
    • Aultman Health Foundation · Canton, United StatesRecruiting→Suspended
    • Providence Portland Medical Center · Portland, United StatesRecruiting→Suspended
    • Providence Saint Vincent Medical Center · Portland, United StatesRecruiting→Suspended
    Site contacts Changed at 4 sites. See the sites
    Show 4 sites
    • Midwestern Regional Medical Center · Zion, United StatesContact removed •••0745Contact removed (no phone or email listed)
    • Aultman Health Foundation · Canton, United StatesContact removed C•••@aultman.com · •••7274Contact removed (no phone or email listed)
    • Providence Portland Medical Center · Portland, United StatesContact removed C•••@providence.org · •••2614Contact removed (no phone or email listed)
    • Providence Saint Vincent Medical Center · Portland, United StatesContact removed C•••@providence.org · •••2614Contact removed (no phone or email listed)
  18. Oct 1, 2026
    2 sites added, 1 site removed
    Show 2 added (2 United States)
    • Vandalia Health/CAMC Institute for Academic Medicine · Charleston, United States
    • Memorial Hospital of Laramie County · Cheyenne, United States
    Show 1 removed
    • West Virginia University Charleston Division · Charleston, United States
    Site contacts Changed at 2 sites. See the sites
    Show 2 sites
    • Regions Hospital · Saint Paul, United StatesContact person changed (no phone or email listed)
    • Cancer Center of Western Wisconsin · New Richmond, United StatesContact person changed (no phone or email listed)
  19. Sep 30, 2026
    1 site added
    Show site
    • Doctors Cancer Center · Manati, Puerto Rico
    + 1 other change: verification date
  20. Sep 29, 2026
    1 site added. 2 sites changed recruiting status (2 now recruiting)
    Show 2 sites
    • Florida Cancer Specialists - Sarasota Downtown · Sarasota, United StatesSuspended→Recruiting
    • Florida Cancer Specialists - Venice Pinebrook · Venice, United StatesSuspended→Recruiting
    Show site
    • Miami Cancer Institute · Miami, United States
    Site contacts Changed at 3 sites. See the sites
    Show 3 sites
    • Florida Cancer Specialists - Sarasota Downtown · Sarasota, United StatesContact added C•••@flcancer.com · •••9930Contact added (no phone or email listed)
    • Florida Cancer Specialists - Venice Pinebrook · Venice, United StatesContact added C•••@flcancer.com · •••9930Contact added (no phone or email listed)
    • West Virginia University Charleston Division · Charleston, United StatesContact none listed→C•••@vandaliahealth.org
  21. Sep 28, 2026
    2 sites changed recruiting status (2 now suspended)
    Show 2 sites
    • Florida Cancer Specialists - Sarasota Downtown · Sarasota, United StatesRecruiting→Suspended
    • Florida Cancer Specialists - Venice Pinebrook · Venice, United StatesRecruiting→Suspended
    Site contacts Changed at 2 sites. See the sites
    Show 2 sites
    • Florida Cancer Specialists - Sarasota Downtown · Sarasota, United StatesContact removed C•••@flcancer.com · •••9930Contact removed (no phone or email listed)
    • Florida Cancer Specialists - Venice Pinebrook · Venice, United StatesContact removed C•••@flcancer.com · •••9930Contact removed (no phone or email listed)
  22. Sep 25, 2026
    1 site added
    Show site
    • United Hospital Center · Bridgeport, United States

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07061977
Responsible party
Sponsor
First posted
Jul 14, 2025
Start date
Nov 5, 2025
Primary completion
Dec 31, 2030 (estimated)
Completion
Dec 31, 2030 (estimated)
Last update
Nov 9, 2026

Study contacts

Jyoti S Mayadev
principal investigator · NRG Oncology

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Carboplatin · Paclitaxel · Pembrolizumab

Start the discussion